BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 22665066)

  • 1. BCR-ABL regulates death receptor expression for TNF-related apoptosis-inducing ligand (TRAIL) in Philadelphia chromosome-positive leukemia.
    Kuroda I; Inukai T; Zhang X; Kikuchi J; Furukawa Y; Nemoto A; Akahane K; Hirose K; Honna-Oshiro H; Goi K; Kagami K; Yagita H; Tauchi T; Maeda Y; Sugita K
    Oncogene; 2013 Mar; 32(13):1670-81. PubMed ID: 22665066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oncogenic fusion E2A-HLF sensitizes t(17;19)-positive acute lymphoblastic leukemia to TRAIL-mediated apoptosis by upregulating the expression of death receptors.
    Zhang X; Inukai T; Hirose K; Akahane K; Kuroda I; Honna-Oshiro H; Kagami K; Goi K; Nakamura K; Kobayashi M; Endo M; Yagita H; Kurosawa H; Thomas Look A; Honda H; Inaba T; Nakazawa S; Sugita K
    Leukemia; 2012 Dec; 26(12):2483-93. PubMed ID: 22743623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of T-cell acute lymphoblastic leukemia to tumor necrosis factor--related apoptosis-inducing ligand-mediated apoptosis.
    Akahane K; Inukai T; Zhang X; Hirose K; Kuroda I; Goi K; Honna H; Kagami K; Nakazawa S; Endo K; Kubota T; Yagita H; Koyama-Okazaki T; Sugita K
    Exp Hematol; 2010 Oct; 38(10):885-95. PubMed ID: 20670671
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TNF-related apoptosis-inducing ligand (TRAIL) frequently induces apoptosis in Philadelphia chromosome-positive leukemia cells.
    Uno K; Inukai T; Kayagaki N; Goi K; Sato H; Nemoto A; Takahashi K; Kagami K; Yamaguchi N; Yagita H; Okumura K; Koyama-Okazaki T; Suzuki T; Sugita K; Nakazawa S
    Blood; 2003 May; 101(9):3658-67. PubMed ID: 12506034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endoplasmic reticulum stress inducers, but not imatinib, sensitize Philadelphia chromosome-positive leukemia cells to TRAIL-mediated apoptosis.
    Zhang X; Inukai T; Akahane K; Hirose K; Kuroda I; Honna H; Goi K; Kagami K; Tauchi T; Yagita H; Sugita K
    Leuk Res; 2011 Jul; 35(7):940-9. PubMed ID: 21466892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting pro-apoptotic trail receptors sensitizes HeLa cervical cancer cells to irradiation-induced apoptosis.
    Maduro JH; de Vries EG; Meersma GJ; Hougardy BM; van der Zee AG; de Jong S
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):543-52. PubMed ID: 18793956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitization of imatinib-resistant CML cells to TRAIL-induced apoptosis is mediated through down-regulation of Bcr-Abl as well as c-FLIP.
    Park SJ; Kim MJ; Kim HB; Kang CD; Kim SH
    Biochem J; 2009 Apr; 420(1):73-81. PubMed ID: 19203346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histone deacetylase inhibitors synergistically potentiate death receptor 4-mediated apoptotic cell death of human T-cell acute lymphoblastic leukemia cells.
    Sung ES; Kim A; Park JS; Chung J; Kwon MH; Kim YS
    Apoptosis; 2010 Oct; 15(10):1256-69. PubMed ID: 20582477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cotreatment with apicidin overcomes TRAIL resistance via inhibition of Bcr-Abl signaling pathway in K562 leukemia cells.
    Park SJ; Kim MJ; Kim HB; Sohn HY; Bae JH; Kang CD; Kim SH
    Exp Cell Res; 2009 Jul; 315(11):1809-18. PubMed ID: 19268463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic targeting of gene expression by siRNAs directed against BCR-ABL transcripts in a patient with imatinib-resistant chronic myeloid leukemia.
    Koldehoff M; Elmaagacli AH
    Methods Mol Biol; 2009; 487():451-66. PubMed ID: 19301661
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Snake venom toxin from Vipera lebetina turanica sensitizes cancer cells to TRAIL through ROS- and JNK-mediated upregulation of death receptors and downregulation of survival proteins.
    Park MH; Jo M; Won D; Song HS; Song MJ; Hong JT
    Apoptosis; 2012 Dec; 17(12):1316-26. PubMed ID: 23007278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Kinetics of proliferation, differentiation and transcription of genes regulating apoptosis in cultured human BCR/ABL+ Ph+-cells].
    Akhlynina TV; Gerasimova LP; Sarkisian GP; Borovkova TV; Dukhovenskaia EA; Manakova TE; Naĭdenova NM; Timofeev AM; Grineva NI
    Tsitologiia; 2007; 49(10):889-900. PubMed ID: 18074781
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular characterization and sensitivity of STI-571 (imatinib mesylate, Gleevec)-resistant, Bcr-Abl-positive, human acute leukemia cells to SRC kinase inhibitor PD180970 and 17-allylamino-17-demethoxygeldanamycin.
    Nimmanapalli R; O'Bryan E; Huang M; Bali P; Burnette PK; Loughran T; Tepperberg J; Jove R; Bhalla K
    Cancer Res; 2002 Oct; 62(20):5761-9. PubMed ID: 12384536
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ewing's sarcoma family tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5.
    Mitsiades N; Poulaki V; Mitsiades C; Tsokos M
    Cancer Res; 2001 Mar; 61(6):2704-12. PubMed ID: 11289151
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
    Izeradjene K; Douglas L; Delaney A; Houghton JA
    Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
    Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
    Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
    Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
    Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of a new Philadelphia chromosome-positive acute lymphoblastic leukemia cell line (SK-9) with T315I mutation.
    Okabe S; Tauchi T; Ohyashiki K
    Exp Hematol; 2010 Sep; 38(9):765-72. PubMed ID: 20471447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5.
    Zhang Y; Zhang B
    Mol Cancer Res; 2008 Dec; 6(12):1861-71. PubMed ID: 19074831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.